Inovio Sees Cash Runway Into Late 2027
The biotech company's projection follows FDA approval of VOCERYQ for recurrent respiratory papillomatosis and a November public offering.
Updated on Nov. 11, 2026 in Cancer

Inovio Pharmaceuticals projects its cash runway extends into late Q4 2027, following the U.S. Food and Drug Administration's October 30, 2026 approval of VOCERYQ. The forecast includes proceeds from a public offering that closed November 9, 2026.
Why it matters
The projection gives the company a funded window to launch its newly approved therapy for a rare disease in which surgery is the standard treatment and growths often return. The forecast excludes VOCERYQ revenue and any future fundraising, so it rests on financing already secured.
The runway projection rests on a company cash-forecast filing, which combines $48.4 million held on September 30, 2026 with $80.5 million in offering proceeds and $10.9 million from warrant exercises against about $21 million in assumed Q4 operational burn. The forecast excludes VOCERYQ sales and future financing, and the company reported a $38 million working capital deficit as of September 30.
The players
Inovio Pharmaceuticals
Inovio Pharmaceuticals is a publicly traded biotechnology company developing DNA medicines, including its therapy for recurrent respiratory papillomatosis.
The details
Inovio said VOCERYQ was approved to reduce surgery frequency in adults with recurrent respiratory papillomatosis, a rare disease in which growths in the airway are typically removed surgically and often return. The company expects the product to be available to order and ship about 60 days after approval, with a full commercial launch planned for Q1 2027.
Timeline
September 30, 2026: Inovio reports $48.4 million in cash and a $38 million working capital deficit.
October 30, 2026: The FDA approves VOCERYQ under its accelerated approval program.
November 9, 2026: A public offering closes, yielding $80.5 million in net proceeds.
Q4 2026: The forecast assumes about $21 million in operational net cash burn.
Q1 2027: Inovio plans a full commercial launch of VOCERYQ.
Big Picture
The approval is an accelerated-approval decision, a pathway the FDA uses to bring treatments for serious conditions to market sooner based on earlier evidence. Inovio's launch therefore proceeds on the pathway's terms rather than through a traditional full approval.
Patients with recurrent respiratory papillomatosis may see a new option aimed at reducing how often surgery is needed to remove airway growths. Availability depends on the company's planned order-and-ship timeline and its Q1 2027 full commercial launch.
The takeaway
For patients managing recurrent airway growths, the approval adds a treatment aimed at reducing surgical frequency, though its real-world availability will depend on the company's launch timing.
What happens next
Inovio expects VOCERYQ to be available to order and ship about 60 days after approval and plans to apply for conditional marketing authorization in Europe before the end of 2026.
Further reading
Explore more on Cancer developments and treatment approvals.










